You might have already forgotten your New Year’s resolution to eat better, but Canaccord Genuity analyst Scott Van Winkle is always thinking about nutrition and food. Scott has a history of recommending nutrition and food related stocks such as Green Mountain Coffee Roasters Inc. (NASDAQ:GMCR), Herbalife Ltd. (NYSE:HLF) and Enzymotec Ltd (NASDAQ:ENZY). Scott’s recommendations have earned him the number 261 spot out of 2396 analysts and a 2.5% average return over S&P-500. Many of Scott’s most recent recommendations are already earning him positive returns.
Following the announcement that The Coca-Cola Company (NYSE:KO) and Green Mountain Coffee Roasters Inc. (NASDAQ:GMCR) will be entering a strategic partnership, Scott recommended BUY Green Mountain Coffee Roasters Inc. (NASDAQ:GMCR). “10-year global strategic partnership with The Coca-Cola Company (NYSE:KO) is all that really matters today, instantly validating Green Mountain Coffee Roasters Inc. (NASDAQ:GMCR)’s Keurig Cold platform. A $1.25 billion investment by Coca-Cola in Green Mountain Coffee Roasters Inc. (NASDAQ:GMCR) sweetens the importance of the deal.” Scott also believes that, “As one of the most richly valued brands in the world and the leading soft drink company in the world, we believe The Coca-Cola Company (NYSE:KO) is more important to Keurig Cold than Starbucks certainly was to Keurig brewing.” Scott has earned himself a +14.0% return over S&P-500.
Herbalife Ltd. (NYSE:HLF), a nutrition and skin-care product company, has also recently surfaced in the news over its growth in China. Scott recommended BUY HLF in January and February of this year and earned +1.4% and lost -3.6% over S&P-500 respectively. In January Scott said BUY HLF noting, “Beyond the fundamental outlook for Herbalife Ltd. (NYSE:HLF) in China that we believe doesn’t warrant any measurable discounting in the shares, yesterday’s correction probably serves to increase the likelihood that HLF steps up its buyback activity in a significant way.” This time, Scott received a positive response of +1.4% over S&P-500.
However, his most recent BUY recommendation has currently resulted in a loss of -3.6% over S&P-500. Scott argued the company’s “efficient business model and the continual global distribution of its products will keep pushing double-digit growth in both earnings and revenue.” However despite this small loss, there is still time for his recommendation to turn around.
One of Scott’s most impressive returns was his BUY Enzymotec Ltd (NASDAQ:ENZY) recommendation in late 2013. Scott believed Enzymotec, a manufacturer of nutritional goods, was “well positioned to drive sustained growth in the highly attractive nutrition market, translating into strong sales, margin and earnings momentum.” Scott was right, and earned +59.2% over S&P-500!
Whether you are looking to shape up this Spring, or simply looking to shape up your portfolio, be sure to take a look Scott’s recommendations. However, before you make any financial decisions, be sure to review each analyst’s recommendation history by downloading TipRanks, and start making informed decisions with advice you can trust.